JAC Advance Access originally published online on February 4, 2004
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Journal of Antimicrobial Chemotherapy (2004) 53, 474-479
© 2004 The British Society for Antimicrobial Chemotherapy
Methicillin-resistant Staphylococcus aureus bacteraemia diagnosed at hospital admission: distinguishing between community-acquired versus healthcare-associated strains
1 Division of Infectious Diseases and 2 Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
Received 29 July 2003; returned 19 October 2003; revised 23 November 2003; accepted 11 December 2003
Background: Methicillin-resistant Staphylococcus aureus (MRSA) infections diagnosed at hospital admission are often referred to as community-acquired. This designation may include MRSA strains previously acquired in a healthcare setting (healthcare-associated) as well as those that have emerged from community-based S. aureus strains.
Methods: To understand further the epidemiology of MRSA from the community, a case-control study was performed. During 1997–2002, 254 patients with and without MRSA bacteraemia at hospital admission were studied.
Results: All patients with MRSA bacteraemia in the first 24 h of hospital admission had a recent exposure to a healthcare setting: true community-acquired MRSA was not detected. Independent risk factors for healthcare-associated MRSA bacteraemia, defined as MRSA bacteraemia in the first 24 h of hospital admission among patients with a recent exposure to a healthcare setting or intervention, included previous MRSA infection or colonization (OR = 17, P < 0.001), cellulitis (OR = 4, P = 0.006), presence of a central venous catheter (OR = 3, P < 0.001) and skin ulcers (OR = 3, P = 0.007).
Conclusions: In this study, MRSA bacteraemia diagnosed in the first 24 h of hospital admission represented healthcare-associated MRSA strains and not true community-acquired strains. The clinical characteristics associated with healthcare-associated MRSA bacteraemia can assist clinicians in targeting measures to prevent cross-transmission and may help to streamline empirical vancomycin therapy.
Keywords: S. aureus, methicillin resistance, risk factors
* Corresponding author. Beth Israel Deaconess Medical Center, Harvard Medical School, Division Infectious Diseases, Kennedy-6, 330 Brookline Ave., Boston, MA 02215, USA. Tel: +1-617-667-8127; Fax: +1-617-632-0766; E-mail: etaccone{at}bidmc.harvard.edu
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R. M. Klevens, R. J. Gorwitz, and A. S. Collins Methicillin-Resistant Staphylococcus aureus: A Primer for Dentists J Am Dent Assoc, October 1, 2008; 139(10): 1328 - 1337. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Nathwani, M. Morgan, R. G. Masterton, M. Dryden, B. D. Cookson, G. French, D. Lewis, and on behalf of the British Society for Antimicrobial Guidelines for UK practice for the diagnosis and management of methicillin-resistant Staphylococcus aureus (MRSA) infections presenting in the community J. Antimicrob. Chemother., May 1, 2008; 61(5): 976 - 994. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Tacconelli, G. De Angelis, M. A. Cataldo, E. Pozzi, and R. Cauda Does antibiotic exposure increase the risk of methicillin-resistant Staphylococcus aureus (MRSA) isolation? A systematic review and meta-analysis J. Antimicrob. Chemother., January 1, 2008; 61(1): 26 - 38. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Phillips, C. MacDougall, and D. A Holdford Analysis of Empiric Antimicrobial Strategies for Cellulitis in the Era of Methicillin-Resistant Staphylococcus aureus Ann. Pharmacother., January 1, 2007; 41(1): 13 - 20. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. E Sabol, K. L Echevarria, and J. S Lewis II Community-Associated Methicillin-Resistant Staphylococcus aureus: New Bug, Old Drugs Ann. Pharmacother., June 1, 2006; 40(6): 1125 - 1133. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. G. Gemmell, D. I. Edwards, A. P. Fraise, F. K. Gould, G. L. Ridgway, R. E. Warren, and on behalf of the Joint Working Party of the Britis Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK J. Antimicrob. Chemother., April 1, 2006; 57(4): 589 - 608. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. H. Kollef, A. Shorr, Y. P. Tabak, V. Gupta, L. Z. Liu, and R. S. Johannes Epidemiology and Outcomes of Health-care-Associated Pneumonia: Results From a Large US Database of Culture-Positive Pneumonia Chest, December 1, 2005; 128(6): 3854 - 3862. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. H Wyllie, T. E A Peto, and D. Crook MRSA bacteraemia in patients on arrival in hospital: a cohort study in Oxfordshire 1997-2003 BMJ, October 29, 2005; 331(7523): 992. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. F. Webb, E. M. C. D'Agata, P. Magal, and S. Ruan A model of antibiotic-resistant bacterial epidemics in hospitals PNAS, September 13, 2005; 102(37): 13343 - 13348. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Wylie and D. L. Nowicki Molecular Epidemiology of Community- and Health Care-Associated Methicillin-Resistant Staphylococcus aureus in Manitoba, Canada J. Clin. Microbiol., June 1, 2005; 43(6): 2830 - 2836. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.-H. Kim, W.-B. Park, K.-D. Lee, C.-I. Kang, J.-W. Bang, H.-B. Kim, E.-C. Kim, M.-d. Oh, and K.-W. Choe Outcome of inappropriate initial antimicrobial treatment in patients with methicillin-resistant Staphylococcus aureus bacteraemia J. Antimicrob. Chemother., August 1, 2004; 54(2): 489 - 497. [Abstract] [Full Text] [PDF]
|
|